It appears plausible that our findings might be relevant in other tumor entities where antiangiogenic and anti-EGFR strategies are therapeutic options (e.g., the EGFR inhibitor lapatinib was investigated in combination with bevacizumab in breast cancer [35]), however to our knowledge, no results of two-arm comparative trials have been reported as yet. Here, EGFR is linked to neoplasm.